DAPA-HF One Year on: What Have You Missed?
Published: 31 July 2020
-
Views:
177 -
Likes:
7
-
Views:
177 -
Likes:
7
-
11m 57sPart 1 Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF John JV McMurray
-
12m 26sPart 2 Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF Piotr Ponikowski
Overview
This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focused upon analysing the DAPA-HF SGLT2 randomised clinical trial and subsequent sub-analysis data that been published over the last 12 months.
Agenda
- Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF - John McMurray (University of Glasgow, Glasgow, UK)
- Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF - Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL)
- DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF- Scott Solomon (Brigham & Women’s Hospital, Boston, US)
- Impact of Dapagliflozin Treatment on KCCQ - Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US)
- Dapagliflozin and Diuretic Use in Patients With HFrEF - Alice Jackson (University of Glasgow, Glasgow, UK)
More from this programme
Part 1
Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF
Part 2
Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF
Part 3
DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF
Part 4
Impact of Dapagliflozin Treatment on KCCQ
Part 5
Dapagliflozin and Diuretic Use in Patients With HFrEF
Faculty Biographies
Scott Solomon
Director, Noninvasive Cardiology / Professor
Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction.
He received his AB from Williams College and his MD from Harvard Medical School.